As a result, the company said it will start clinical trials on the gum for alleviating the symptoms of irritable bowel syndrome (IBS).
IBS patient trial
Volunteers took part in a study involving a single 10mg dose of cannabidiol (CBD) and 30mg of CBD to find out the concentration of CBD in the blood after chewing one CanChew Plus Gum for 30 minutes.
The 30mg dosage showed excellent results and this data will be used to determine the optimal concentration in an IBS patient trial.
“These results show excellent bioavailability for CBD may be achieved via our proprietary chewing gum delivery system, so that patients suffering from IBS may have symptomatic relief using an easy-to-use solution,” said George Anastassov, CEO, AXIM Biotech.
“We believe we can match or improve the bioavailability profile for CBD compared to other delivery systems such as smoking or oral intake.
“We look forward to entering a clinical trial and making available our cannabis-based medicine to patients suffering from IBS and other gastrointestinal disorders as soon as possible.”
He added the data will be essential as it starts the trial to prove the efficacy of CBD for treatment for IBS.
“We saw through the study the 30mg dosage of CBD rendered the most favorable results and will use this data to decide the most optimal dosage for patients in the clinical trial,” he said.
AXIM Biotech focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products.
Its products include CanChew, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis.